In a recent development for Jasper Therapeutics (JSPR, Financial), BTIG analyst Justin Zelin has updated his position on the company's stock. Although Zelin maintains a 'Buy' rating, there has been a significant change in the price target for JSPR.
The price target has been lowered from a prior $64.00 to a new level of $20.00. This adjustment represents a decrease of 68.75% from the previous target, indicating a revised outlook on the stock's potential valuation.
Despite the adjustment in the price target, the 'Buy' rating suggests confidence in the long-term prospects of Jasper Therapeutics (JSPR, Financial). This move by BTIG reflects an updated analysis while sustaining a positive sentiment on the stock's future performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Jasper Therapeutics Inc (JSPR, Financial) is $47.88 with a high estimate of $70.00 and a low estimate of $15.00. The average target implies an upside of 1,474.84% from the current price of $3.04. More detailed estimate data can be found on the Jasper Therapeutics Inc (JSPR) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Jasper Therapeutics Inc's (JSPR, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
